Navigation Links
Halozyme to Host Third Quarter 2013 Financial Results Conference Call
Date:11/1/2013

SAN DIEGO, Nov. 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2013 on Friday, November 8, 2013 at 8:30 a.m. ET/5:30 a.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date pre-market, Halozyme will release financial results for the third quarter 2013.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 423197.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com and follow us on www.twitter.com/HALOTherapeutic.

Investor Contact:
David Ramsay
Halozyme Therapeutics
858-704-8260
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
818-522-8411
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
2. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
3. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
4. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
5. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
6. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
7. Halozyme Reports Second Quarter 2013 Financial Results
8. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
9. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
10. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
(Date:1/18/2017)... enero de 2017  Hoy, en el Foro Económico ... iniciativa global para avanzar el acceso a la prevención ... de renta baja y baja-media (LICs y LMICs). ... crisis, particularmente en países de renta baja y media, ... las muertes relacionadas con NCD. El objetivo de Access ...
(Date:1/18/2017)... -- With an annual growth ranging from 6% to 10%, South East Asia,s ... Expo, March 22-24, 2017) serves the industry by fostering the regional discourse - ... Investment Forum ASEAN -- India ... content Enhanced business matchmaking program Roadshows ... ...
Breaking Medicine Technology:
(Date:1/17/2017)... Marne, Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking ... those who choose to lurk in the corners and commit the crime of stalking, a ... drug use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: ...
(Date:1/17/2017)... Illinois (PRWEB) , ... January 17, 2017 , ... For ... Breast Cancer Symposium (SABCS) or those who desire a more intimate review and analysis ... Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, 2017 ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting ... Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted ... providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... A ... named winners of the fourth Cradle to Cradle Product Design Challenge , the ... fourth in a series of six circular design challenges scheduled to run through early ...
Breaking Medicine News(10 mins):